Sage Investment Advisers LLC Buys New Position in Johnson & Johnson $JNJ

Sage Investment Advisers LLC bought a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 5,081 shares of the company’s stock, valued at approximately $1,052,000.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. Brighton Jones LLC lifted its position in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares during the period. United Bank lifted its position in shares of Johnson & Johnson by 110.7% in the 1st quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after acquiring an additional 4,876 shares during the period. Sivia Capital Partners LLC lifted its position in shares of Johnson & Johnson by 13.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after acquiring an additional 692 shares during the period. Wealth Group Ltd. lifted its position in shares of Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after acquiring an additional 168 shares during the period. Finally, Schnieders Capital Management LLC. lifted its position in shares of Johnson & Johnson by 9.8% in the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock worth $11,255,000 after acquiring an additional 6,584 shares during the period. Institutional investors own 69.55% of the company’s stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J reported strong Phase 3 results for Erleada (apalutamide) in prostate cancer. The PROTEUS study met both primary endpoints, showing a lower risk of metastasis or death and a much higher likelihood of little to no cancer remaining after surgery, which could expand the drug’s role and support future oncology sales. Article: J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study
• Positive Sentiment: RYBREVANT FASPRO showed durable responses in advanced head and neck cancer in the OrigAMI-4 study, including a 42% confirmed response rate and complete responses in more than one-third of responders. J&J also submitted the therapy to the FDA for approval in this setting, adding another potential growth driver if the label is expanded. Article: RYBREVANT FASPRO pivotal data show strong and durable responses in advanced head and neck cancer
• Positive Sentiment: Several pieces highlighted J&J as a strong dividend stock, reinforcing its appeal as a low-beta, income-oriented healthcare name for investors seeking stability. Article: Is Johnson & Johnson one of the best dividend paying stocks to buy right now?
• Neutral Sentiment: A market recap article noted that JNJ stock was down 2.4% and questioned whether it is time to sell, but it did not provide a new company-specific catalyst beyond the recent move. Article: Johnson & Johnson stock price down 2.4% – time to sell?

Analyst Ratings Changes

A number of equities analysts have recently issued reports on JNJ shares. Wells Fargo & Company increased their target price on Johnson & Johnson from $240.00 to $263.00 and gave the stock an “overweight” rating in a report on Wednesday, April 15th. Leerink Partners upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 target price for the company in a research report on Wednesday, May 13th. Citigroup raised their target price on Johnson & Johnson from $274.00 to $285.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Morgan Stanley set a $283.00 target price on Johnson & Johnson in a research report on Wednesday, April 15th. Finally, Raymond James Financial raised their target price on Johnson & Johnson from $237.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 15th. Twenty investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $253.04.

Johnson & Johnson Trading Down 0.1%

Shares of JNJ opened at $225.16 on Monday. The stock has a fifty day moving average price of $233.02 and a two-hundred day moving average price of $225.07. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a 52-week low of $149.04 and a 52-week high of $251.71. The company has a market cap of $542.01 billion, a price-to-earnings ratio of 26.03, a PEG ratio of 2.21 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.02. The firm had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Analysts predict that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be paid a $1.34 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. This represents a $5.36 annualized dividend and a dividend yield of 2.4%. Johnson & Johnson’s payout ratio is 61.97%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.